Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster, Daniel M. Whalen, Ayşegül Özen, et al.
Cancer Cell (2016) Vol. 29, Iss. 4, pp. 477-493
Open Access | Times Cited: 202

Showing 26-50 of 202 citing articles:

Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 23, pp. 7089-7097
Open Access | Times Cited: 111
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications
Haifeng Hu, Ye Zeng, Yi Qin, et al.
Acta Pharmacologica Sinica (2021) Vol. 42, Iss. 11, pp. 1725-1741
Open Access | Times Cited: 102
Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Elvira Pelosi, Germana Castelli, Ugo Testa
Biomedicines (2017) Vol. 5, Iss. 4, pp. 65-65
Open Access | Times Cited: 99
Discovery of a selective inhibitor of doublecortin like kinase 1
Fleur M. Ferguson, Behnam Nabet, Srivatsan Raghavan, et al.
Nature Chemical Biology (2020) Vol. 16, Iss. 6, pp. 635-643
Open Access | Times Cited: 98
The next tier of EGFR resistance mutations in lung cancer
Hannah L. Tumbrink, Alena Heimsoeth, Martin L. Sos
Oncogene (2020) Vol. 40, Iss. 1, pp. 1-11
Closed Access | Times Cited: 95
Current Insights of BRAF Inhibitors in Cancer
Bogos Agianian, Evripidis Gavathiotis
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 14, pp. 5775-5793
Closed Access | Times Cited: 87
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Ningning Yan, Sanxing Guo, Huixian Zhang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 57
Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
Vincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 40
Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects
Rizwan Qureshi, Bin Zou, Tanvir Alam, et al.
IEEE/ACM Transactions on Computational Biology and Bioinformatics (2022) Vol. 20, Iss. 1, pp. 238-255
Open Access | Times Cited: 38
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4627-4643
Open Access | Times Cited: 27
Architecture of the MKK6-p38α complex defines the basis of MAPK specificity and activation
Pauline Juyoux, Ioannis Galdadas, Dorothea Gobbo, et al.
Science (2023) Vol. 381, Iss. 6663, pp. 1217-1225
Open Access | Times Cited: 22
Signaling from RAS to RAF: The Molecules and Their Mechanisms
Hyesung Jeon, Emre Tkacik, Michael J. Eck
Annual Review of Biochemistry (2024) Vol. 93, Iss. 1, pp. 289-316
Closed Access | Times Cited: 12
Slower CDK4 and faster CDK2 activation in the cell cycle
Wengang Zhang, Yonglan Liu, Hyunbum Jang, et al.
Structure (2024) Vol. 32, Iss. 8, pp. 1269-1280.e2
Closed Access | Times Cited: 9
CoHIT: a one-pot ultrasensitive ERA-CRISPR system for detecting multiple same-site indels
Yin Liu, Xinyi Liu, Dongyi Wei, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes
Lynn Lee, Anjelika Gasilina, Jayeeta Roychoudhury, et al.
JCI Insight (2017) Vol. 2, Iss. 3
Open Access | Times Cited: 84
A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
Grace R. Anderson, Peter Winter, Kevin Lin, et al.
Cell Reports (2017) Vol. 20, Iss. 4, pp. 999-1015
Open Access | Times Cited: 83
High frequency of H3 K27M mutations in adult midline gliomas
Azadeh Ebrahimi, Marco Skardelly, Martin U. Schuhmann, et al.
Journal of Cancer Research and Clinical Oncology (2019) Vol. 145, Iss. 4, pp. 839-850
Closed Access | Times Cited: 65
Targeting the MAPK Pathway in RAS Mutant Cancers
S.G. Hymowitz, Shiva Malek
Cold Spring Harbor Perspectives in Medicine (2018) Vol. 8, Iss. 11, pp. a031492-a031492
Open Access | Times Cited: 61
Altered conformational landscape and dimerization dependency underpins the activation of EGFR by α C– β 4 loop insertion mutations
Zheng Ruan, Natarajan Kannan
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 35
Open Access | Times Cited: 61
RAF kinase dimerization: implications for drug discovery and clinical outcomes
Tilman Brummer, Campbell McInnes
Oncogene (2020) Vol. 39, Iss. 21, pp. 4155-4169
Closed Access | Times Cited: 59
Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
Zhenfang Du, Benjamin P. Brown, Soyeon Kim, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 55
Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases
Nicole S. Persky, Desiree Hernandez, Mariana DoCarmo, et al.
Nature Structural & Molecular Biology (2020) Vol. 27, Iss. 1, pp. 92-104
Closed Access | Times Cited: 53
Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling
Christos Adamopoulos, Tamer A. Ahmed, Maxwell R. Tucker, et al.
Cancer Discovery (2021) Vol. 11, Iss. 7, pp. 1716-1735
Open Access | Times Cited: 50
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis
Jia Chen, Ailin Zhao, Minghui Duan, et al.
Leukemia (2021) Vol. 36, Iss. 2, pp. 573-576
Closed Access | Times Cited: 43
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis
Xinxin Cao, Minghui Duan, Ailin Zhao, et al.
American Journal of Hematology (2021) Vol. 97, Iss. 2, pp. 203-208
Open Access | Times Cited: 42

Scroll to top